Kotler DP, Tierney AR, Ferraro R, Francisco A, Wang J, Pierson Jr RN. The magnitude of body cell mass depletion determines the timing of
death from wasting in AIDS. Am J Clin Nutr.1989;50:444-447.
Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction and survival in patients
with AIDS. Am J Gastroenterol.1989;84:1288-1293.
Linden CP, Allen S, Serufilira A.
et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med.1992;116:320-328.
Sellmeyer DE, Grunfeld C. 1996 Endocrine and metabolic disturbances in human immunodeficiency
virus infection and the acquired immune deficiency syndrome. Endocr Rev.1996;17:518-52.
Dobs AS, Dempsey MA, Landeson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med.1988;84:611-615.
Croxon TC, Chapman WE, Miller LK, Levitt CD, Senie R, Zumoff B. Changes in the hypothalamic pituitary-gonadal axis in human immunodeficiency
virus-infected hypogonadal men. J Clin Endocrinol Metab.1989;68:317-321.
Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS.1991;5:729-733.
DePaepe ME, Vuletin JC, Lee MH, Rojas-Corona RR, Waxman M. Testicular atrophy in homosexual AIDS patients. Hum Pathol.1989;20:572-578.
Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in HIV wasting syndrome. J Acquir Immune Defic Syndr Retrovirol.1994;7:46-51.
Salehian B, Jacobson D, Grafe M, McCutchan A, Swerdloff R. Pituitary-testicular axis during HIV infection: a prospective study. Presented at: 18th Annual Meeting of the American Society of Andrology;
April 15-19, 1993; Tampa, Fla. Abstract 9.
Grinspoon S, Corcoran C, Lee K.
et al. Loss of lean body and muscle mass correlates with androgen levels in
hypogondal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab.1996;81:4051-4058.
Arver SA, Sinha-Hikim I, Beall G, Shen R, Guerrero M, Bhasin S. Serum dihydrotestosterone and testosterone levels in human immunodeficiency
virus-infected men with and without weight loss. J Androl.1999;20:611-618.
Dobs AS, Few WL, Blackman MR, Harman SM, Hoover DR, Graham NMH. Serum hormones in men with human immunodeficiency virus-associated
wasting. J Clin Endocrinol Metab.1996;81:4108-4112.
Bhasin S, Storer TW, Berman N, Yarasheski K, Cleveneger B, Casaburi R. A replacement dose of testosterone increase fat-free mass, and muscle
size in hypogonadal men. J Clin Endocrinol Metab.1997;82:407-413.
Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration
in men with acquired hypogonadism. J Clin Endocrinol Metab.1996;81:4358-4365.
Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein
synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab.1996;81:3469-3475.
Bhasin S, Storer TW, Asbel-Sethi N.
et al. Effects of testosterone replacement with a non-genital, transdermal
system: Androderm, in human immunodeficiency virus-infected men with low testosterone
levels. J Clin Endocinol Metab.1998;83:3155-3162.
Grinspoon S, Corcoran C, Askari H.
et al. Effects of androgen adminsitration in men with the AIDS wasting syndrome:
a randomized, double-blind, placebo-controlled trial. Ann Intern Med.1998;129:18-26.
Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS.1997;11:1347-1352.
Dobs A, Cofrancesco J, Nolten WE.
et al. The use of a transscrotal testosterone delivery system in the treatment
of patients with weight loss related to human immunodeficiency virus infection. Am J Med.1999;107:126-132.
Strawford A, Barbieri T, Neese R.
et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men
with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20:137-146.
Strawford A, Barbieri T, Van Loan M.
et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal
men with HIV-related weight loss. JAMA.1999;281:1282-1290.
Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men
with and without hypogonadism. J Clin Psychopharmacol.1999;19:19-27.
Gold J, High HA, Li Y.
et al. Safety and efficacy of nandrolone decanoate for treatment of wasting
in patients with HIV infection. AIDS.1996;10:745-752.
Berger JR, Pall L, Winfield D. Effect of anabolic steroids on HIV-related wasting myopathy. South Med J.1993;86:865-866.
Hengge UR, Baumann M, Maleba R.
et al. Oxymethalone promotes weight gain in patients with advanced human immunodeficiency
virus (HIV-1) infection. Br J Nutr.1996;75:129-138.
Poles MA, Meller JA, Lin A, Weiss WR, Gocke M, Dietrich DT. Oxandrolone as a treatment for AIDS-related weight loss and wasting. Presented at: the Infectious Disease Society of America Conference;
September 19, 1996; New York, NY.
Bucher G, Berger DS, Fields-Gardner C, Reiter JR. A prospective study of the safety and effect of nandrolone decanoate
in HIV-positive patients [abstract]. In: Program and abstracts of the 11th International Conference on
AIDS; July 7-12, 1996; Vancouver, British Columbia.
Sattler FR, Jaque SV, Schroeder ET.
et al. Effect of pharmacological doses of nandrolone decanoate and progressive
resistance training in immunodeficient patients infected with the human immunodeficiency
virus. J Clin Endocrinol Metab.1999;84:1268-1276.
Rebouche CJ, Pearson GA, Serfass RE, Roth CW, Finley JW. Evaluation of nuclear magentic resonance spectroscopy for determination
of deuterium abundance in body fluids: application to measurement of total
body water in human infants. Am J Clin Nutr.1987;45:373-380.
Bhasin S, Storer TW, Berman N.
et al. The effects of supraphysiologic doses of testosterone on muscle size
and strength in normal men. N Engl J Med.1996;335:1-6.
Sinha-Hikim I, Arver S, Beall G.
et al. The use of a sensitive, equilibrium dialysis method for the measurement
of free testosterone levels in healthy, cycling women, and in HIV-infected
women. J Clin Endocrinol Metab.1998;83:1312-1318.
Hays RD, Cunningham WE, Ettl MK, Beck CK, Shapiro MF. Health-related quality of life in HIV disease. Assessment.1995;2:363-380.
MacArthur RD, Levine SD, Birk TJ. Supervised exercise training improves cardiovascular fitness in HIV-infected
persons. Med Sci Sports Exerc.1993;25:684-688.
Stringer WW, Berezovskaya M, O'Brien WA, Beck CK, Casaburi R. The effect of exercise training on aerobic fitness, immune indices,
and quality of life in HIV+ patients. Med Sci Sports Exerc.1998;30:11-16.
Roubenoff R, McDermott A, Weiss L.
et al. Short-term progressive resistance training increases strength and lean
body mass in adults infected with human immunodeficiency virus. AIDS.1999;13:231-239.
Waters D, Danska J, Hardy K.
et al. Recombinant human growth hormone, insulin-like growth factor I, and
combination therapy in AIDS-associated wasting: a randomized, double-blind,
placebo-controlled trial. Ann Intern Med.1996;125:8665-8672.
Schambelan M, Mulligan K, Grunfeld C.
et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med.1995;125:873-882.
Von Roenn JH, Armstrong D, Kotler D.
et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med.1994;121:393-399.